Benzinga | May 4, 2021 06:51AM EDT

AbCellera Announces Second Antibody From Its Collaboration With Eli Lilly Has Entered Clinical Trials In Patients With Mild-To-Moderate COVID-19

AbCellera (NASDAQ:ABCL) today announced that a second antibody from its collaboration with Eli Lilly and Company (Lilly), LY-CoV1404, has entered clinical trials in patients with mild-to-moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trials to evaluate LY-CoV1404 alone and together with other monoclonal antibodies.